Search

everythinglearnresearchcommunity

for

Search:↓

Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.

Six key genes can predict bladder cancer outcomes and may serve as prognostic biomarkers.

The length of the CAG repeat in the androgen receptor gene affects the risk and progression of prostate cancer, BPH, infertility, and undermasculinized genitalia.

Using existing drugs for new purposes could be a cost-effective way to treat chest pain and non-clogged heart arteries, with some drugs for lung blood pressure showing promise but needing more testing.

The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.

The ABI1 gene contributes to prostate cancer progression and treatment resistance.

Blocking Prostaglandin D₂ may help treat hair loss.

Progestogens are essential in menopausal hormone therapy to prevent uterine cancer and must be chosen carefully based on individual needs.

Ghrelin and its receptors likely aren't risk factors for PCOS.

Brassinosteroids may be useful in treating cancer, infections, and other diseases.

Genetic factors in PCOS are complex, with potential influences from the MC4R gene.

Three specific 4-azasteroid-2-oximes showed strong enzyme inhibition, but less than finasteride.

Certain natural compounds called terpenes may help prevent prostate cancer.

No significant link was found between the studied genes and female hair loss in the Polish population.

Prostaglandin F2α analogs show promise for treating certain types of hair loss but need more research for other skin conditions.

A new genetic change causing early stop in the androgen receptor gene was found in a patient with androgen insensitivity syndrome.

The research found that androgens help control blood flow in the rat prostate through a specific binding site.

Certain changes to the B-ring of androgen receptor ligands can increase their effectiveness for potential treatments of muscle and bone conditions.

Three genes, BMP4, POSTN, and WNT5A, may help treat keloids.

Activating cannabinoid receptor 1 reduces certain keratin levels, potentially aiding psoriasis treatment.

Provenge extends prostate cancer survival by about 4 months.

Trienones are more effective at inhibiting the enzyme linked to hair loss than dienones.

Different types of androgens bind differently to two receptors, AR1 and AR2, in Atlantic croaker's brain and ovarian tissues, suggesting these receptors may control different androgen actions in fish.

Retinoids increase steroid sulfatase activity in leukemia cells through RARα/RXR and involves certain pathways like phosphoinositide 3-kinase and ERK-MAP kinase.

Progesterone and allopregnanolone increase glycine release in rat brain cells.

Genetic profiling can improve androgenetic alopecia treatment by predicting drug response and minimizing side effects.

Certain gene variants are linked to a higher risk of polycystic ovary syndrome, hair loss, and obesity in women from western Saudi Arabia.

A protein called PCBP2 controls the production of a hair growth protein by interacting with its genetic message and is linked to hair loss when this control is disrupted.

Two gene areas linked to male pattern baldness found, more research needed.